Why Amylin Receptor Agonism Changes the Weight Loss Equation

GLP-1 receptor agonists have proven that pharmacological satiety signaling can deliver meaningful, sustained weight loss — but their ceiling is set by a single receptor pathway. Amylin receptor agonism operates through complementary and partially non-overlapping mechanisms, and combining the two within one molecule or co-administration regimen is the central therapeutic hypothesis behind CagriSema and Amycretin.

Amylin is a 37-amino acid polypeptide hormone co-secreted with insulin from pancreatic beta cells. Its native half-life of approximately 15–20 minutes is considerably longer than GLP-1’s approximately 2 minutes before degradation by dipeptidyl peptidase-4 (DPP-4), but both require engineered analogs for therapeutic application. Amylin acts via amylin receptors 1–3 (AMYR1-3) across multiple organ systems, inhibiting glucagon secretion, delaying gastric emptying, and signaling satiety through mechanisms that are partially distinct from GLP-1 receptor activation. This mechanistic complementarity — not redundancy — is the pharmacological rationale that patent filings from Novo Nordisk A/S and MedImmune Limited (AstraZeneca) use to justify the co-agonist approach.

The GLP-1 receptor (GLP-1R) is a G protein-coupled receptor activated by glucagon-like peptide-1, secreted from intestinal L-cells in response to food intake. Retrieved Novo Nordisk patent filings describe GLP-1R as mediating insulin secretion stimulation, glucagon suppression, gastric emptying inhibition, and satiety signaling. Semaglutide, the first GLP-1R agonist approved as a tablet (Rybelsus®), established proof-of-concept that engineered GLP-1 analogs can be orally administered — a precedent that directly informs the oral Amycretin formulation strategy. Other approved GLP-1R agonist products cited in the patent record include dulaglutide (Trulicity®), exenatide (Byetta®, Bydureon®), liraglutide (Victoza®), lixisenatide (Lyxumia®), and semaglutide (Ozempic®), establishing GLP-1R as a clinically validated target upon which the amylin co-agonist strategy is designed to build.

The disease context across all retrieved filings is consistent: obesity and its metabolic comorbidities — type 2 diabetes, cardiovascular disease, non-alcoholic steatohepatitis (NASH), and cognitive impairment — are the primary therapeutic targets. According to WHO, obesity affects hundreds of millions of individuals globally and drives a cascade of comorbidities that make it one of the most significant unmet medical needs of our time. The co-agonist hypothesis is that activating both GLP-1R and AMYR simultaneously produces greater weight loss than either mechanism alone.

From Single Molecules to Combination Regimens: The Therapeutic Modality Map

The GLP-1/amylin co-agonist space is not a single modality — it encompasses at least six distinct therapeutic approaches, ranging from unified single-molecule co-agonists to multi-component combination regimens pairing amylin analogues with dual or tri-receptor agonists.

Single-Molecule Co-agonists: The Amycretin Approach

The dominant modality in the retrieved patent dataset is a single peptide compound engineered to simultaneously agonize both GLP-1R and AMYR1-3. Multiple Novo Nordisk patent filings across jurisdictions describe compounds comprising a GLP-1 receptor agonist pharmacophore fused or conjugated with an amylin receptor agonist pharmacophore. Critically, these filings describe compounds that may incorporate one, two, or three protraction moieties — structural features that extend half-life and enable oral administration. The pharmaceutical formulations are described as suitable for oral administration, a potentially significant differentiation from injectable GLP-1R agonists currently on the market.

Combination Regimens: Zealand Pharma’s Multi-Partner Amylin Platform

Zealand Pharma A/S takes a distinct approach: pairing amylin analogues with dual agonist partners in co-administered regimens rather than a unified single molecule. Two distinct combination strategies appear in the patent record. The first, from a 2024 WO filing, pairs an acylated dual GLP-1/GLP-2 receptor agonist with an amylin analogue — GLP-2R engagement may offer intestinal trophic benefits and metabolic stabilization complementary to weight-loss effects. The second, from 2025 WO and NZ filings, combines an amylin analogue with a GIPR/GLP-1R dual agonist (tirzepatide-class molecules), targeting additive weight loss and metabolic benefits. This positions Zealand’s amylin analogue IP as a broadly combinable platform compatible with multiple dual agonist partners.

AMYR-Selective Agonism: AstraZeneca’s Differentiation Axis

MedImmune Limited (AstraZeneca) filed a 2025 WO patent covering combinations of amylin receptor agonists and GLP-1R agonists, with specific attention to AMYR agonists that have selectivity for AMYR relative to calcitonin receptor. This selectivity framing implies that earlier amylin analogs — such as pramlintide — with less receptor selectivity may have had suboptimal profiles. The filing explicitly addresses lean muscle mass loss as a known clinical liability of GLP-1 agonists, framing AMYR-selective agonism as a potential clinical solution and a freedom-to-operate differentiation strategy relative to Novo Nordisk’s scaffold.

Assignee Landscape: Who Controls the Core IP

Patent-driven innovation dominates over academic literature activity in this space. Three organizations account for all significant filing activity in the retrieved dataset: Novo Nordisk A/S, Zealand Pharma A/S, and MedImmune Limited (AstraZeneca).

Novo Nordisk A/S is the most active and dominant assignee in this dataset by a significant margin. Retrieved results include at least 10 distinct patent filings across WO, US, CA, IL, IN, AU, BR, and TW jurisdictions, all originating from PCT/EP2021/086494 (WO 2022/129526) and its national phase entries, plus the 2025 tri-agonist WO filing. The active legal status in the US (as of October 2023) and Australia (March 2025) indicates successful examination progress, consistent with a compound that has advanced beyond early-stage preclinical work. According to WIPO, PCT national phase prosecution at this scale and pace is characteristic of molecules in or approaching clinical development.

“Any competitor seeking to develop a unified GLP-1/amylin co-agonist molecule will need to design around PCT/EP2021/086494 and its national phase entries — and the oral formulation claim layer adds additional IP complexity for follow-on programs.”

Zealand Pharma A/S is the second-most prominent assignee for amylin-containing combination strategies. Its 2024 WO filing covering GLP-1/GLP-2 + amylin combination and its 2025 WO and NZ filings covering GIPR/GLP-1R + amylin combinations span four jurisdictions (WO, NZ, CN, and a 2019 SG acylated dual agonist filing). MedImmune Limited’s 2025 WO filing represents AstraZeneca’s entry into the space, with a specific AMYR selectivity framing that could support freedom-to-operate and non-obvious claims relative to Novo Nordisk’s scaffold. EPO examination of these filings will be a key watch point for the competitive IP landscape over the next 18–36 months.

Tri-agonism, Oral Delivery, and the Lean Muscle Problem

Three emerging directions in the 2024–2025 patent record signal where the GLP-1/amylin co-agonist field is heading: escalation to tri-receptor agonism, oral delivery of co-agonist molecules, and the growing recognition of lean muscle mass loss as a clinical liability that combination approaches must address.

The GLP-1/GIP/Amylin Tri-agonist: Next-Level Escalation

Novo Nordisk’s 2025 WO patent on a tri-agonist combining GLP-1R, GIP receptor, and amylin receptor agonism in a single molecule represents the most advanced modality escalation in this dataset. Designed for once-weekly administration, this approach seeks to add tirzepatide-class GIP pharmacology to the Amycretin-type co-agonist scaffold. The once-weekly dosing design criteria and description of improved pharmacokinetic properties are design parameters typically defined based on in vivo pharmacokinetic-pharmacodynamic modeling, suggesting this molecule is further along than an early-stage concept. According to FDA guidance on combination product development, demonstrating additive or synergistic benefit across receptor pathways is a key regulatory expectation for novel multi-agonist therapeutics.

Oral Delivery: Amycretin’s Potential Market Differentiation

The Novo Nordisk co-agonist patent family consistently describes oral administration suitability as a key formulation attribute, with a dedicated Brazilian filing specifically claiming pharmaceutical formulations for oral delivery. Oral formulation-level IP protection — layered on top of the core compound claims — adds complexity for any follow-on developer attempting to create a competing oral GLP-1/amylin co-agonist. Given that semaglutide (Rybelsus®) established proof-of-concept for oral GLP-1R agonism, oral Amycretin may represent a distinct market opportunity over injectable CagriSema, particularly for patients who prefer or require non-injectable administration.

Lean Muscle Mass: A Field-Wide Design Criterion

Multiple 2024–2025 filings across assignees flag lean mass loss as a key limitation of GLP-1R agonism. The MedImmune Limited 2025 WO filing explicitly references lean muscle mass loss as a known clinical liability of GLP-1 and glucagon/GLP-1 agonists, and frames AMYR-selective agonism as a potential clinical solution. This framing references known human clinical observations from predecessor programs, signaling that the combination rationale is informed by clinical-stage data. The field-wide recognition of this issue means that future obesity combination claims — including those incorporating amylin — will increasingly require body composition data (not just body weight reduction) as evidence of clinical differentiation.

Strategic Implications for Drug Developers and IP Teams

The GLP-1/amylin co-agonist patent landscape has several clear strategic implications for organizations active in obesity drug development, IP strategy, and competitive intelligence.

For drug developers, the breadth of Novo Nordisk’s IP estate — spanning the core GLP-1/amylin co-agonist compound, oral pharmaceutical formulations, and a 2025 tri-agonist escalation — means that any competitor developing a unified single-molecule GLP-1/amylin co-agonist will face substantial design-around requirements. The PCT/EP2021/086494 family and its national phase entries in at least 8 jurisdictions create a patent thicket that extends across the major pharmaceutical markets. The tri-agonist (GLP-1/GIP/amylin) filing from Novo Nordisk in 2025 signals an intent to extend IP coverage into a next-generation molecule class, consistent with maximizing exclusivity across successive drug generations.

For IP strategists, MedImmune Limited’s AMYR selectivity framing offers a potential differentiation pathway: demonstrating that AMYR agonists with selectivity for AMYR over calcitonin receptor have non-obvious advantages could support freedom-to-operate claims and novel composition claims distinct from Novo Nordisk’s scaffold. Zealand Pharma’s combinatorial approach — pairing amylin analogue IP with multiple dual agonist partners — positions its amylin program as a broadly licensable platform, potentially enabling partnership with whichever dual agonist platform demonstrates the strongest clinical weight loss. Monitoring prosecution status at the EPO and WIPO for these families will be essential for any organization active in this space.

For clinical teams, the emerging body composition data requirement is a critical planning signal. Lean muscle mass loss has been explicitly flagged as a clinical liability of GLP-1R agonism in multiple 2024–2025 patent filings, and amylin receptor agonism is being positioned as a mitigator. Programs that generate body composition endpoints — not just body weight reduction — in early clinical trials will be better positioned for regulatory differentiation and commercial label claims. The indication breadth consistently claimed across Novo Nordisk filings (obesity, diabetes, cardiovascular disease, NASH, cognitive impairment) also signals a broad label strategy that clinical trial design should anticipate from the outset.